about
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa RicaEvolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancerAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacyEpidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasiaEffect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine TrialSingle nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancerRationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaCross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registryEffectiveness of a simple rapid human papillomavirus DNA test in rural NigeriaThe expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levelsEffects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS).Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Determinants of seropositivity among HPV-16/18 DNA positive young women.Digital tools for collecting data from cervigrams for research and training in colposcopy.Preparing digitized cervigrams for colposcopy research and education: determination of optimal resolution and compression parameters.Interobserver agreement in the evaluation of digitized cervical images.Common genetic variants and risk for HPV persistence and progression to cervical cancer.Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trialsComprehensive control of human papillomavirus infections and related diseasesLack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties.A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia.Impact of improved classification on the association of human papillomavirus with cervical precancer.An evaluation by midwives and gynecologists of treatability of cervical lesions by cryotherapy among human papillomavirus-positive women.Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfectionResults of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducibleReassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.Sequence imputation of HPV16 genomes for genetic association studies.Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3Cervical histopathology variability among laboratories: a population-based statewide investigation
P50
Q21089767-FD0C53CA-CC24-4D21-92C2-B4B503007B0FQ21135368-6C3503FE-C2BE-4808-85E5-4751461D2A28Q22299118-54D66135-CE27-403D-9BA9-1B70FDD7C48AQ24607403-E38BBB00-303E-42BA-AF58-4AC5FC571766Q26828840-FC6DDAF8-6C50-468D-A5AF-F76FADFF701BQ26995703-42CC613B-26B7-499A-B079-594033DB7E90Q28296557-908E700E-E620-45BB-956D-A3A2DD91323DQ28607942-32B5A373-23FF-40CB-BF35-8FCD6F5CD51DQ28730698-D13A0B1D-CFCA-40B0-92B9-78AD261F018AQ30300329-9B282949-34D8-4213-9545-0657CA86F82DQ30353668-F58C984F-EA3F-4FF1-A2E1-3B2A08B2A214Q30354591-D09D39AF-FB98-4540-AE6D-D02ADCDEB5B1Q30354637-59395D8B-7161-4BD5-A644-D271AAC6F347Q30407482-6BB9D708-6783-4947-ACE1-894C5FA3A117Q30409771-FBBA477A-E307-4FCA-A22D-41F024670EFEQ30415760-C64B75F9-4D85-4A5B-A780-3E6D1E7A0B2AQ30442823-20F887EB-AB12-4DE8-A937-0F80C19F7A94Q30446333-124D8CF6-73C0-434C-8A39-B6866F695895Q30534669-A9DDFE9F-9E3A-4E23-8C08-887036643B06Q30670234-3CF361BE-DD52-4BC2-BC63-8EEA872DDABEQ30685686-4C9A63D2-8207-4D92-8777-CD17C988F048Q30970916-10DF832A-B415-4F1D-830F-11AEC1255E64Q30986936-F2CFC5DE-904C-46EC-8076-6CFC82C11C82Q31027622-811F10B7-F699-4A7C-9B69-21ABB1654E1DQ33230321-588BABAB-8744-4893-9A7A-82D80DA01F95Q33300920-1DB958C8-25F7-439A-A104-78EEF89B09B4Q33525051-C6645E34-AB73-4DD7-8BE2-AFD1D6BD3D8FQ33698774-E006781B-199E-4703-BB8F-DFB1A6BFE52DQ33699365-DF93570C-E363-41A8-8C90-D2E5DFD1F79AQ33772648-AFE60670-05CB-4AB2-9E27-E0A0E4136473Q33781541-7520ADB0-1458-4D19-B6F8-9FE9FBF20AD1Q33793914-FC206A51-A4C9-4F52-89BC-C9BE247CBB5BQ33883581-B77C073D-22D6-48C8-B040-770649E658C4Q33902505-16EC1A2E-6231-4E28-A90F-5E0C0CBE2247Q33947813-746D3CB1-56A1-444A-BF2C-783A9BB8E1A9Q33951232-8B502C7A-0297-4A44-AEFA-CE453D36CF32Q33951517-5E14C626-9CC2-4C24-BF99-0B7CC305A6B3Q33952360-6363CE0E-DA82-462B-9A0E-3FE138921223Q33984185-8542E845-2A47-4AA5-8893-1F78E467C016Q34017556-77883F19-8C13-4777-BDED-F737952B3C53
P50
name
Mark Schiffman
@ast
Mark Schiffman
@en
Mark Schiffman
@nl
type
label
Mark Schiffman
@ast
Mark Schiffman
@en
Mark Schiffman
@nl
prefLabel
Mark Schiffman
@ast
Mark Schiffman
@en
Mark Schiffman
@nl
P214
118148207942500342208
P31
P7859
viaf-118148207942500342208